SynAct Pharma AB (FRA:8F8) Cyclically Adjusted FCF per Share: €-0.22 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8F8 SynAct Pharma AB FRA:8F8
18 GF Score
Price €1.80
! 1 Warning Sign
View Full Analysis

What is SynAct Pharma AB Cyclically Adjusted FCF per Share?

SynAct Pharma AB FRA:8F8 +1.13% 18 Cyclically Adjusted FCF per Share is €-0.22 as of Mar. 2026. GuruFocus rates FRA:8F8 with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

SynAct Pharma AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.057. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.22 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-18), SynAct Pharma AB's current stock price is €1.796. SynAct Pharma AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.22. SynAct Pharma AB's Cyclically Adjusted Price-to-FCF of today is .


SynAct Pharma AB  (FRA:8F8) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


SynAct Pharma AB Cyclically Adjusted FCF per Share Related Terms


SynAct Pharma AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for SynAct Pharma AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SynAct Pharma AB Cyclically Adjusted FCF per Share Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SynAct Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.22

FRA:8F8 vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, SynAct Pharma AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SynAct Pharma AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where SynAct Pharma AB's Cyclically Adjusted Price-to-FCF falls into.


FRA:8F8
18GF Score
SynAct Pharma AB FRA:8F8
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynAct Pharma AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SynAct Pharma AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.057/133.5600*133.5600
=-0.057

Current CPI (Mar. 2026) = 133.5600.

SynAct Pharma AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.284 101.019 -0.375
201609 0.207 101.138 0.273
201612 -0.049 102.022 -0.064
201703 -0.052 102.022 -0.068
201706 -0.027 102.752 -0.035
201709 -0.031 103.279 -0.040
201712 -0.030 103.793 -0.039
201803 -0.031 103.962 -0.040
201806 -0.051 104.875 -0.065
201809 -0.044 105.679 -0.056
201812 -0.038 105.912 -0.048
201903 -0.030 105.886 -0.038
201906 0.009 106.742 0.011
201909 -0.020 107.214 -0.025
201912 -0.064 107.766 -0.079
202003 -0.043 106.563 -0.054
202006 -0.024 107.498 -0.030
202009 -0.034 107.635 -0.042
202012 -0.039 108.296 -0.048
202103 -0.040 108.360 -0.049
202106 -0.061 108.928 -0.075
202109 -0.068 110.338 -0.082
202112 -0.075 112.486 -0.089
202203 -0.061 114.825 -0.071
202206 -0.126 118.384 -0.142
202209 -0.134 122.296 -0.146
202212 -0.070 126.365 -0.074
202303 -0.086 127.042 -0.090
202306 -0.092 129.407 -0.095
202309 -0.039 130.224 -0.040
202312 -0.051 131.912 -0.052
202403 -0.028 132.205 -0.028
202406 -0.080 132.716 -0.081
202409 -0.051 132.304 -0.051
202412 -0.037 132.987 -0.037
202503 -0.054 132.825 -0.054
202506 -0.035 133.699 -0.035
202509 -0.044 133.480 -0.044
202512 -0.041 133.390 -0.041
202603 -0.057 133.560 -0.057

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.22 mean?
SynAct Pharma AB (FRA:8F8) has a Cyclically Adjusted FCF per Share of €-0.22 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on SynAct Pharma AB and its competitors.
Is SynAct Pharma AB's Cyclically Adjusted FCF per Share too high?
SynAct Pharma AB's current Cyclically Adjusted FCF per Share is €-0.22. Overall, SynAct Pharma AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does SynAct Pharma AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
SynAct Pharma AB's Cyclically Adjusted FCF per Share of €-0.22 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on SynAct Pharma AB and its competitors. SynAct Pharma AB's current Cyclically Adjusted FCF per Share is €-0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynAct Pharma AB stock overvalued right now?
SynAct Pharma AB (FRA:8F8) has a current Cyclically Adjusted FCF per Share of €-0.22. The current Cyclically Adjusted FCF per Share is €-0.22. SynAct Pharma AB's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For SynAct Pharma AB (FRA:8F8), the current Cyclically Adjusted FCF per Share is €-0.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SynAct Pharma AB Business Description

Other Exchanges SYNACT:Sweden8F8:Germany
Address Scheelevagen 2, Lund, SWE, 223 63
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
18GF Score

Get the complete analysis for FRA:8F8

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.80
Price